Abstract
We have performed a non-randomised GVHD prophylaxis trial comparing cyclosporin/methotrexate with in vivo/ex vivo T cell depletion with the monoclonal antibodies Campath 1G/1M in patients with acute leukaemias in first complete remission. We observed significantly less acute and chronic GVHD, neutropenic fever and severe mucositis in the T cell depletion group. The incidence of graft rejection and relapses was no higher than in the cyclosporin/methotrexate group. There is a trend in favour of improved disease-free survival in the in vivo/ex vivo T cell depletion group (80% vs. 62%).
Publication types
-
Clinical Trial
-
Comparative Study
MeSH terms
-
Acute Disease
-
Adolescent
-
Adult
-
Alemtuzumab
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bone Marrow Transplantation
-
Cyclosporine / therapeutic use
-
Cytomegalovirus Infections / complications
-
Disease-Free Survival
-
Female
-
Graft vs Host Disease / mortality
-
Graft vs Host Disease / prevention & control*
-
Humans
-
Immunosuppressive Agents / adverse effects
-
Immunosuppressive Agents / therapeutic use*
-
Leukemia / mortality
-
Leukemia / therapy*
-
Male
-
Methotrexate / therapeutic use
-
Middle Aged
-
Recurrence
-
Remission Induction
-
Retrospective Studies
-
Risk Factors
-
T-Lymphocytes / drug effects*
-
Transplantation, Homologous
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm
-
Immunosuppressive Agents
-
Alemtuzumab
-
Cyclosporine
-
Methotrexate